Navigation Links
AEterna Zentaris Announces Appointment of New Board Member
Date:12/9/2009

QUEBEC CITY, Dec. 9 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, is pleased to announce the appointment of Pierre Lapalme to its Board of Directors. A seasoned professional in the pharmaceutical industry, Mr. Lapalme has over the course of his career held numerous senior management positions in various global life sciences companies. He is former Senior Vice-President, Sales and Marketing for Ciba-Geigy (which subsequently became Novartis) and former Chief Executive Officer and Chairman of the Board of Rhone-Poulenc Pharmaceuticals Inc. in Canada and in North America, as well as Executive Vice-President and Chief Executive Officer of Rhone-Poulenc-Rorer Inc. North America (now sanofi aventis), where he supervised the development, manufacturing and sales of prescription products in North and Central America. Mr. Lapalme served on the Board of the National Pharmaceutical Council USA and was a Board member of the Pharmaceutical Manufacturers Association of Canada, where he played a leading role in reinstituting patent protection for pharmaceuticals. Until recently, he was Board member and Chairman of the Board of Sciele Pharma Inc. which was acquired by Shionogi and Co. Ltd. Mr. Lapalme is currently Chairman of the Board of Biomarin, Inc. He studied at the University of Western Ontario and at INSEAD, France.

"Mr. Lapalme has a proven track record and extensive background in the pharmaceutical industry", said Juergen Ernst, Executive Chairman of AEterna Zentaris. "We believe that his wealth of experience in drug development as well as in sales and marketing will be of great assistance to us as we focus on bringing our late-stage oncology compounds closer to market."

About AEterna Zentaris Inc
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
2. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
4. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
5. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
6. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
7. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
8. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
9. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
10. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
11. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Dublin ... the addition of the  "Micro Market Monitor : ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The ... segments in the chromatography market. The market was ... to reach $2.0 billion by 2019, at a ...
(Date:9/19/2014)... LONDON , September 19, 2014 ... Spain , available today on PharmaBoardroom.com ... of the Eurozone crisis that rocked the Spanish economy in ... the Spanish pharma community has remained pragmatic in times of ... is still the fifth biggest European market, and the ...
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
(Date:9/18/2014)... 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep Research ... and "2014 Deep Research Report on Global and ... database. Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... Global and China Acetic Acid Industry" is a ... China and Global Acetic Acid Market. ...
Breaking Biology Technology:Micro Market Monitor : Global Pre-packed Chromatography Columns 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4
... body, then alarm bells start ringing. Such clumps, ... type 2 diabetes, formerly called adult-onset diabetes. If ... might be able to treat such diseases more efficiently. ... the Helmholtz-Zentrum Dresden-Rossendorf and the university in Aarhus, Denmark, ...
... The Plasma Protein Therapeutics Association (PPTA) applauds the ... Drugs Act ( H.R. 2672 ) and ( S. ... therapies that treat patients with rare diseases by eliminating barriers ... on plasma protein therapies are coping with a very rare ...
... (NASDAQ: GPRO ) today reported financial results for ... million and non-GAAP earnings per share (EPS) of $0.51.   ... products in the second quarter of 2011, while supply chain ... sales a year ago," said Carl Hull, the Company,s president ...
Cached Biology Technology:In the pursuit of dangerous clumps 2In the pursuit of dangerous clumps 3PPTA Praises Legislation That Protects the Treatment of Rare Diseases 2Gen-Probe Reports Financial Results for the Second Quarter of 2011 2Gen-Probe Reports Financial Results for the Second Quarter of 2011 3Gen-Probe Reports Financial Results for the Second Quarter of 2011 4Gen-Probe Reports Financial Results for the Second Quarter of 2011 5Gen-Probe Reports Financial Results for the Second Quarter of 2011 6Gen-Probe Reports Financial Results for the Second Quarter of 2011 7Gen-Probe Reports Financial Results for the Second Quarter of 2011 8Gen-Probe Reports Financial Results for the Second Quarter of 2011 9Gen-Probe Reports Financial Results for the Second Quarter of 2011 10Gen-Probe Reports Financial Results for the Second Quarter of 2011 11Gen-Probe Reports Financial Results for the Second Quarter of 2011 12Gen-Probe Reports Financial Results for the Second Quarter of 2011 13Gen-Probe Reports Financial Results for the Second Quarter of 2011 14
(Date:9/21/2014)... what was previously thought, newborn immune T cells may ... bacteria, according to a new study led by King,s ... to that of adults, babies may still be able ... published in the journal Nature Medicine . , ... types of immune cells, including neutrophils which play an ...
(Date:9/21/2014)... a protein therapy that disrupts the process that causes ... travel through the blood stream and start aggressive new ... as metastasis, can cause cancer to spread with deadly ... to cancer fall prey to metastatic forms of the ... who describes a new therapeutic approach in Nature ...
(Date:9/19/2014)... by researchers from several Harvard University labs in ... and aspiring researchers with the intellectual raw materials ... from soft, flexible materials. , With the advent ... advances in manufacturing technology, soft robotics is emerging ... from conventional rigid robot design, but working with ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4Soft robotics 'toolkit' features everything a robot-maker needs 2
... - A study comparing a University of Pennsylvania ... to the traditional American method has shown that 80 ... traditional method are actually at risk for developing osteoarthritis ... The results indicate that traditional scoring of radiographs that ...
... most established fisheries certifier is failing on its promises ... leading fisheries experts from the University of British Columbia ... California at San Diego and elsewhere. Established in ... of the world,s largest fish retailers, the Marine Stewardship ...
... but estrogen might not be the reason. Testosterone, though, could ... the lab of Florida State University researcher Mohamed Kabbaj, associate ... a five-year, $1.8 million grant from the National Institute of ... research team also is working to identify the role of ...
Cached Biology News:Hip dysplasia susceptibility in dogs may be underreported, according to Penn Vet comparative study 2Hip dysplasia susceptibility in dogs may be underreported, according to Penn Vet comparative study 3Hip dysplasia susceptibility in dogs may be underreported, according to Penn Vet comparative study 4Seafood stewardship questionable: UBC-Scripps experts 2Seafood stewardship questionable: UBC-Scripps experts 3Why does anxiety target women more? FSU researcher awarded $1.8 million grant to find out 2
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: